Seer (SEER) Q2 2026 earnings review
Revenues Decelerate as Seer Banks Everything on a Massive H2 Ramp
Seer’s Q2 results show a business struggling with severe growth friction. Revenue fell 23% YoY to $3.1 million, driven by macroeconomic headwinds, academic funding delays, and extended sales cycles. Despite generating only $5.9 million in the first half of the year, management reaffirmed its full-year guidance of $16-$18 million. This implies a massive and highly risky acceleration in the second half of the year. While the company successfully reined in operating expenses (-19% YoY) and defended gross margins (rebounding to 49% from 35% in Q1), the core narrative centers on defending its intellectual property against imitators while waiting for a stalled commercial engine to reignite.
🐂 Bull Case
Gross margins recovered to 49% (up from 35% in Q1). Management's aggressive cost-cutting drove a 19% YoY reduction in OpEx, helping to protect the $209.5M cash runway.
Third-party validation continues to grow, highlighted by a Nature Genetics publication and AI-driven multi-cancer screening data presented by Korea University.
🐻 Bear Case
Revenue declined 23% YoY. The core product and service engines are stalling amid academic funding freezes and extended customer evaluation cycles.
Hitting the $17M guidance midpoint requires H2 revenues of ~$11.1M, demanding an unprecedented >85% acceleration versus H1 output.
⚖️ Verdict: 🔴
Bearish. While Seer boasts an impressive cash runway and improving cost controls, the top-line degradation (-23% YoY) and reliance on a hockey-stick H2 recovery create substantial execution risk. The emergence of IP litigation against 'imitators' confirms rising competitive friction.
Key Themes
Mathematical Contradiction in Reaffirmed Guidance
Management reaffirmed FY26 revenue guidance of $16-$18 million. However, H1 revenue totals just $5.9 million. To reach the $17 million midpoint, Seer must generate $11.1 million in H2—an average of $5.55 million per quarter. Given the company has never exceeded $4.2 million in a single quarter (25Q4) and is actively citing 'macroeconomic headwinds' and 'elongated sales cycles', this reaffirmed guidance contradicts current operational reality and heavily relies on unproven consumable pull-through assumptions from the 2025 installed base.
Aggressive Defense of Market and Intellectual Property
Faced with what management previously dubbed 'inferior product imitators' competing on price, Seer is shifting to an aggressive legal posture. The U.S. International Trade Commission has opened an investigation into Nanomics Biotechnology's importation of allegedly infringing products, and the European Patent Office maintained claims for Brigham and Women’s Hospital's patent exclusively licensed to Seer. Defending this moat is critical to preserving long-term pricing power for the Proteograph platform.
Macroeconomic Squeeze on Academic Budgets
The macro narrative is worsening. Management explicitly blamed the 23% YoY revenue decline on 'continuing macroeconomic headwinds in academic and government funding' and 'elongation of sales cycles' as customers extend their evaluations. Since academic and government sectors represent roughly 30% to 40% of Seer's historical revenue, this structural budget freeze threatens both instrument adoption and service utilization.
Growing AI Integration and Scientific Validation
The underlying science continues to gain high-profile validation. A major Nature Genetics publication utilized the Proteograph to link genetic variants to disease risk in British South Asians. More importantly, Korea University presented preliminary data at the ASMS conference demonstrating the potential of AI-driven plasma proteomics for multi-cancer screening. This transition from basic discovery to AI-enabled clinical screening use cases represents the core catalyst for broader biobank adoption.
Cost Base Rationalization
While revenue falters, Seer is aggressively shielding its balance sheet. Operating expenses were slashed by 19% YoY to $18.3 million in Q2, primarily through reduced employee compensation and stock-based compensation (which fell from $3.7M to $1.5M YoY). This disciplined cash management ensures the company can weather the current macro storm without dilutive capital raises.
Product Revenue Deceleration
Core product revenue (instruments and consumable kits) fell to $2.3 million from $2.7 million a year ago. For a company relying on the 'razor and blade' model, falling product sales indicate that the installed base is not scaling fast enough to offset the friction in new instrument sales.
Other KPIs
Recovering. After plummeting to 35% in Q1 due to poor fixed cost absorption on low volumes, gross margin rebounded to 49% in Q2. While still slightly below the ~52% seen in mid-2025, it demonstrates that unit economics stabilize quickly when volumes cross the $3M threshold.
Stable. The company consumed roughly $10 million in cash during Q2 (down from $219.5M at the end of Q1). With H1 free cash flow standing at negative $25.3M, the company's current burn rate provides roughly 4 years of runway, granting management significant time to execute their turnaround strategy.
Guidance
Reaffirmed. This implies approximately 3% growth at the midpoint vs FY25. Because H1 2026 revenue was only $5.9M, achieving the $17M midpoint requires an aggressive acceleration to ~$11.1M in H2 2026. This means H2 must grow nearly 88% sequentially compared to H1. Management believes this will be driven by consumable pull-through from the 2025 installed base, but achieving this amidst elongating sales cycles introduces high execution risk.
Key Questions
The H2 Revenue Bridge
With only $5.9 million generated in H1, achieving the $17 million midpoint requires an unprecedented back-half ramp. What specific, contracted milestones or consumable reorder rates give you the confidence to reaffirm this guidance amid elongating sales cycles?
Impact of ITC Investigation
You've initiated an ITC investigation against Nanomics. How material has the financial impact of these 'imitators' been to your pipeline in H1, and what is the expected timeline for a resolution?
Biobank Conversion Timeline
With the Korea University data demonstrating the power of AI-driven proteomics, how is this translating into your commercial pipeline? Are these massive population studies shifting from evaluations to committed product/service orders for H2?